The list will review and designate all site and morphology combinations entered into the software and determine whether the combination is either valid, unlikely, or impossible.
This applies only to cases diagnosed on or after 01/01/2024. For cases diagnosed before this date, the existing standards will remain in place. The source of the information comes from the PathCHART ICD-O-3 validation list and NAACCR site/type edits.
The PathCHART validation list was included as part of the CRStar April 2024 upgrade. The software validates against the SMVL when a user:
- Opens the Diagnosis Maintenance screen for any case diagnosed 01/01/2024 +
- When a histology and/or morphology code is entered
- When the user changes or modifies an existing topography or morphology code
If the combination entered is valid, nothing happens on the screen. If an unlikely or unlisted code is entered, the user will get an alert to verify the combination. And if the code is impossible, the user will receive an alert. Additionally, the field's background color will change, adding an extra alert for the user. The user can ignore the message and move forward in the abstract; however, best practices highly recommend that the user review the combination at that time. If ignored, the user should receive a NAACCR edit when checking edits.
To learn more about how to use PathCHART in CRStar, users can read the Insight “Cancer PathCHART” located in the Abstracting section on the Resource Page. The Resource Page can be accessed via the Help module in the CRStar Cancer Registry Platform. Click below for more information about PathCHART from SEER.